Clinical trial · Observational
Prevalence of Cachexia in Patients Undergoing Chemotherapy
Prevalence and Impact of Cachexia in Cancer Patients Undergoing Chemotherapy
NCT01939340CI-TRIAL-00012053completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cachexia and low nutritional intake are a common phenomena in cancer patients undergoing chemotherapy. The purpose of this study is to assess prevalence of cachexia and low nutritional intake and the impact on quality of life, fatigue and mortality in patients undergoing chemotherapy. Furthermore interactions between these parameters, tumor disease and chemotherapy, respectively.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Nutritional intake
- timeFrame
- 1 day
- description
- Nutritional intake will be assessed by 24h-recall, which will be analysed with regard to macronutritients
Secondary outcomes (3)
- measure
- Cachexia
- timeFrame
- 1 day
- description
- Cachexia will be evaluated using the patient-generated Subjective Global Assessment.
- measure
- Quality of life and fatigue
- timeFrame
- 1 day
- description
- EORTC QLQ C-30 will be used to assess quality of life and additionally cancer-related fatigue will be evaluated using Brief Fatigue Inventory.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing chemotherapy at least in the second cycle. * Patients who have signed a written Informed Consent. Exclusion Criteria: * Patients with implanted pacemaker or defibrillator.
References
Publications (0)
Data not yet available
No reference posted for this study.